Live
FierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical developmentFierceBiotechManaging complexity across biopharma modalitiesNINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBoxEndpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsIlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo FinanceFierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospectMIURA CO.,LTD.Miura Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:MIURF) 2026-06-06 - Seeking Alpha10x Genomics News10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.stFierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetesClinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation
Endpoints News 31 déc. 2025

AbbVie does T cell engager deal in China for Zelgen's DLL3-targeted drug

AbbVie does T cell engager deal in China for Zelgen's DLL3-targeted drug

Original
Contenu indisponible. Consultez la source originale.